drugset
Drugs / cutamesine
last change Sep 2014 re-read 3 minutes ago

cutamesine

also known as SA4503
Developed for
ischemic stroke · major depressive disorder
Investigated by
M's Science Corporation

Trials 2

today NCT00639249 · Ph 2 NCT00551109 · Ph 2
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00639249 Feb 2008 → Jun 2009 ischemic stroke M's Science Corporation Completed Missed primary
Phase 2 NCT00551109 Nov 2007 → Sep 2008 major depressive disorder M's Science Corporation Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2008-03-12 Eisai Inc. M's Science and Eisai Sign Option Agreement for Sigma Agonist SA4503 eisai.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as cutamesine “The σ-1 receptor (Sig-1R) agonist cutamesine (SA4503) enhanced functional recovery after experimental stroke with a treatment initiation window of 48 hours and chronic...” PMID 25270629 ↗ Sep 2014
Known as SA4503 “The σ-1 receptor (Sig-1R) agonist cutamesine (SA4503) enhanced functional recovery after experimental stroke with a treatment initiation window of 48 hours and chronic...” PMID 25270629 ↗ Sep 2014
1

NCT00551109 ↗
Action Activate “The σ-1 receptor (Sig-1R) agonist cutamesine (SA4503) enhanced functional recovery after experimental stroke with a treatment initiation window of 48 hours and chronic...” PMID 25270629 ↗ Sep 2014
Route Oral “Low dose, oral administration, once daily for 8 weeks” NCT00551109 ↗